129 related articles for article (PubMed ID: 9375875)
1. Hormone replacement therapy in systemic lupus erythematosus.
Kreidstein S; Urowitz MB; Gladman DD; Gough J
J Rheumatol; 1997 Nov; 24(11):2149-52. PubMed ID: 9375875
[TBL] [Abstract][Full Text] [Related]
2. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
3. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
4. Menopause hormonal therapy in women with systemic lupus erythematosus.
Sánchez-Guerrero J; González-Pérez M; Durand-Carbajal M; Lara-Reyes P; Jiménez-Santana L; Romero-Díaz J; Cravioto MD
Arthritis Rheum; 2007 Sep; 56(9):3070-9. PubMed ID: 17763408
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease.
Hochman J; Urowitz MB; Ibañez D; Gladman DD
Lupus; 2009 Apr; 18(4):313-7. PubMed ID: 19276299
[TBL] [Abstract][Full Text] [Related]
6. Flares in pediatric systemic lupus erythematosus.
Weiss JE; Sison CP; Ilowite NT; Gottlieb BS; Eberhard BA
J Rheumatol; 2007 Jun; 34(6):1341-4. PubMed ID: 17477466
[TBL] [Abstract][Full Text] [Related]
7. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy.
Bruce IN; Hallett DC; Gladman DD; Urowitz MB
J Rheumatol; 1999 Jul; 26(7):1490-4. PubMed ID: 10405935
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study.
Mok CC; To CH; Mak A; Ma KM
Arthritis Rheum; 2005 Dec; 52(12):3997-4002. PubMed ID: 16320346
[TBL] [Abstract][Full Text] [Related]
9. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity.
Abu-Shakra M; Zalmanson S; Neumann L; Flusser D; Sukenik S; Buskila D
J Rheumatol; 2000 Jul; 27(7):1681-5. PubMed ID: 10914851
[TBL] [Abstract][Full Text] [Related]
10. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.
Buyon JP; Petri MA; Kim MY; Kalunian KC; Grossman J; Hahn BH; Merrill JT; Sammaritano L; Lockshin M; Alarcón GS; Manzi S; Belmont HM; Askanase AD; Sigler L; Dooley MA; Von Feldt J; McCune WJ; Friedman A; Wachs J; Cronin M; Hearth-Holmes M; Tan M; Licciardi F
Ann Intern Med; 2005 Jun; 142(12 Pt 1):953-62. PubMed ID: 15968009
[TBL] [Abstract][Full Text] [Related]
11. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
12. A trial of contraceptive methods in women with systemic lupus erythematosus.
Sánchez-Guerrero J; Uribe AG; Jiménez-Santana L; Mestanza-Peralta M; Lara-Reyes P; Seuc AH; Cravioto MD
N Engl J Med; 2005 Dec; 353(24):2539-49. PubMed ID: 16354890
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with active systemic lupus erythematosus after endstage renal disease.
Szeto CC; Li PK; Wong TY; Leung CB; Lui SF
J Rheumatol; 1998 Aug; 25(8):1520-5. PubMed ID: 9712094
[TBL] [Abstract][Full Text] [Related]
14. Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong.
Szeto CC; Mok HY; Chow KM; Lee TC; Leung JY; Li EK; Tsui TK; Yu S; Tam LS
J Rheumatol; 2008 Jun; 35(6):1031-7. PubMed ID: 18398942
[TBL] [Abstract][Full Text] [Related]
15. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus.
Meier CR; Sturkenboom MC; Cohen AS; Jick H
J Rheumatol; 1998 Aug; 25(8):1515-9. PubMed ID: 9712093
[TBL] [Abstract][Full Text] [Related]
16. The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus.
Holroyd CR; Edwards CJ
Climacteric; 2009 Oct; 12(5):378-86. PubMed ID: 19591008
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus.
Brunner HI; Feldman BM; Bombardier C; Silverman ED
Arthritis Rheum; 1999 Jul; 42(7):1354-60. PubMed ID: 10403262
[TBL] [Abstract][Full Text] [Related]
18. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus.
Ibañez D; Urowitz MB; Gladman DD
J Rheumatol; 2003 Sep; 30(9):1977-82. PubMed ID: 12966601
[TBL] [Abstract][Full Text] [Related]
19. The impact of flare on disease costs of patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
[TBL] [Abstract][Full Text] [Related]
20. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus.
Mok CC; Lau CS; Ho CT; Lee KW; Mok MY; Wong RW
Scand J Rheumatol; 1998; 27(5):342-6. PubMed ID: 9808396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
